Introgen Therapeutics, Inc.'s ADVEXIN Advances as Marketing Authorization Application is Accepted for Review in Europe

AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) and its subsidiary, Gendux Molecular Limited (“Gendux”), announced today the advancement of a Marketing Authorization Application (“MAA”) for ADVEXIN. The MAA, the submission of which was recently announced, has now been accepted for technical review by the European medicines regulatory authority (the “EMEA”) for the treatment of inherited Li-Fraumeni Syndrome (“LFS”) cancers. This acceptance indicates that all administrative issues have been addressed and that the formal technical evaluation of the Application will be conducted under the EMEA’s Exceptional Circumstances Approval rules. If approved, ADVEXIN would be the world’s first treatment specific for an inherited cancer syndrome. ADVEXIN is targeted to reverse one of the most common cancer genetic defects that is inherited in Li-Fraumeni patients and found in the majority of non-inherited cancers.

MORE ON THIS TOPIC